Recent Regulatory Changes in the Cough/Cold Market

Supplements
Download PDF
Melvin R. Pratter, MD
Bart Feldman, BS, BSPharm
Mary Knudtson, DNSc, NP
Gary M. Owens, MD

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: October 17th, 2008 - October 17th, 2009

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for physicians, physician assistants, nurses, pharmacists, and other healthcare stakeholders who wish to enhance their knowledge concerning recent regulatory changes in the cough/cold market.

Learning Objectives
At the completion of this activity participants should be able to:

  • Describe significant points of the US Food and Drug Administration’s rationale for removing nonapproved hydrocodone containing cough suppressants from the market.
  • List cough suppressants containing hydrocodone that remain available today and discuss the appropriate use of these products.
  • Identify and discuss patient education strategies to reinforce the safe and effective use of these products.


Disclosure Statement
The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Faculty Disclosures
Melvin Pratter, MD is on the speaker's bureau for Boehringer Ingelheim, Merck, and Pfizer, and is a consultant for Venture Capital Firm.

Bart Feldman, BS, BSPharm has nothing to disclose.

Mary Knudtson, DNSc, NP has nothing to disclose.

Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.


*Content will include non-FDA-approved uses.

Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of MER, MLI, or Center of Excellence Media, LLC. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MER, MLI, Center of Excellence Media, LLC, and sanofi-aventis. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Related Items
New Directions in the Treatment and Symptom Management of Multiple Sclerosis – Part 2
Gary M. Owens, MD, Samuel F. Hunter, MD, PhD
Interactive Learning published on June 13, 2013
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Gary M. Owens, MD, Bruce L. Hughes, MD , Sonya J. Lewis, RPh, MBA
Supplements published on August 2, 2011
Wellness and Prevention in Chronic Disease Consensus Statement
Gary M. Owens, MD, Nirav R. Shah, MD, MPH, FACP, Michael McLean, RPh, MPA, Kip Piper, MA, FACHE, Doug Burgoyne, PharmD, John Fox, MD, Stacie Heller, Wayne M. Lednar, MD, PhD, Lynne Rothney-Kozlak, Scott R. Taylor, RPh, MBA, F. Randy Vogenberg, RPh, PhD
Supplements published on September 30, 2010
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
Gary M. Owens, MD, Michael Mauro, MD
Supplements published on September 15, 2010
Health System/Regional Variations in the Delivery of Care for Multiple Myeloma
Gary M. Owens, MD, Jatin Shah, MD, Rusty Crawford, RPh, BCOP, Sin (Masha) Lam, PharmD, BCOP, Stephanie S. Minich, PharmD, BCOP
Supplements published on March 30, 2010
ASCO 2009 Highlights on Breast Cancer: A Payer's and Pharmacist's Perspective
Gary M. Owens, MD
Supplements published on September 15, 2009
Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care
Gary M. Owens, MD, Al B. Benson III, MD, FACP, Gary Rice, RPh, MS, MBA
Supplements published on June 30, 2009
Value-Based Oncology Benefit Design: Cost, Quality, and Access Considerations in Colorectal Cancer Care
Gary M. Owens, MD, John Fox, MD
Supplements published on April 30, 2009
Last modified: March 24, 2014